[Correspondence] Combination therapies in non-clear-cell renal cell carcinoma

We read the Article by Laurence Albiges and colleagues1 with great interest. This study provides valuable insights into the treatment of non-clear-cell renal cell carcinoma with a combination of pembrolizumab and lenvatinib. However, the absence of a subgroup analysis focusing on cytoreductive nephrectomy substantially reduces the applicability of the findings, considering the potential effects of cytoreductive nephrectomy in this patient population.